Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30534601 | 1.00 | ESR1 (0.59) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL3185585 | 0.94 | ESR2 (0.68) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL2060640 | 0.90 | ESR2 (0.54) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL15651977 | 0.87 | CA7 (0.55) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL29843388 | 0.87 | CA7 (0.55) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL22271453 | 0.86 | PDK2 (0.54) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL15650896 | 0.83 | NR1H2 (0.45) | ESR1ESR2HRH3NR1H2PDK2 | |
| SCHEMBL22543772 | 0.82 | ESR1 (0.60) | ESR1ESR2HRH3CA7KDM2B | |
| SCHEMBL3181883 | 0.81 | ESR2 (0.88) | ESR1ESR2HRH3PDK2KDM2B | |
| SCHEMBL1265548 | 0.81 | ESR1 (0.63) | ESR1ESR2HRH3CA7KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661918-B1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-111094253-B | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116462680-A | Antitumor compound and application thereof | 南京大美生物制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2021-10-14 | — | — | US | disclosed |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | RECURIUM IP HOLDINGS, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3661918-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D]PYRIMIDIN -3 - ONE ANALOGS | Recurium IP Holdings, LLC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | RECURIUM IP HOLDINGS, LLC | 2020-05-21 | — | — | US | disclosed |
| CN-111094253-A | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs | 里科瑞尔姆IP控股有限责任公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019028008-A1 | 1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS | Zeno Royalties & Milestones, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157112-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | ESR1 560/4885ESR2 346/4885HRH3 3760/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | ESR1 585/4885ESR2 340/4885HRH3 336/4885 |
| US-20210317124-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE ANALOGS | MKI67, BRCA1, CDK4 | ESR1 560/4885ESR2 346/4885HRH3 3760/4885 |
| US-11124518-B2 | L,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one analogs | MKI67, BRCA1, CCND1 | ESR1 664/4885ESR2 244/4885HRH3 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.